Friday 6 November 2026 Export NEO’s income statement to Excel — free account

NeoGenomics, Inc.

NEO Healthcare Diagnostics & Research

NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024.

Revenue: +11.4%
EPS: +72.1%
Free cash flow: −3,724.2%
Total debt: +10.9%

Quarter to September 2026, against a year earlier

Revenue growth 10 yrs

16.55 0.60 −3.50%

Follow NEO

Alert me

Market cap: $2.1B
P/E: 0.0×
Fwd P/E: −68.4×
Dividend yield: —
F-score: 4/9
Altman Z: 1.79
Beneish M: −2.68
Dividend safety: n/a

Overview

NeoGenomics, Inc. (NEO) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, NeoGenomics, Inc. (NEO) trades at a P/S ratio of 2.7×. Over the past ten years it has ranged from 0.9× (July 2025) to 14.7× (December 2020); the current reading is higher than 24% of that period. That is below the Diagnostics & Research industry median of 4.2× and below the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/NEO/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="NeoGenomics, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/NEO/metrics/ps-ratio">NeoGenomics, Inc. (NEO) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	2.1×	(34.45%)
FY2024	3.2×	(6.61%)
FY2023	3.4×	52.74%
FY2022	2.2×	(73.79%)
FY2021	8.5×	(35.75%)
FY2020	13.2×	82.98%
FY2019	7.2×	84.25%
FY2018	3.9×	35.33%
FY2017	2.9×	(0.14%)
FY2016	2.9×	(39.52%)

Period	P/S ratio	Change
Sep 2026	3.0×	21.43%
Jun 2026	2.5×	92.10%
Mar 2026	1.3×	(37.97%)
Dec 2025	2.1×	48.17%
43 more quarters	Free account

Against its own ten years

Low 0.9× High 14.7×

Ten-year median 3.5×

Current reading's percentile 25

Company	P/S ratio
FRNM Freenome, Inc compare	n/m
OPK OPKO Health, Inc. compare	2.6×
NEO NeoGenomics, Inc.	2.7×
CSTL Castle Biosciences, Inc. compare	2.8×
VCYT Veracyte, Inc. compare	3.3×
WGS GeneDx Holdings Corp. compare	4.2×
CDNA CareDx, Inc. compare	8.1×
ADPT Adaptive Biotechnologies Corporation compare	14.5×
PSNL Personalis, Inc. compare	20.7×
Diagnostics & Research industry median	4.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

NeoGenomics, Inc. (NEO) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on NEO

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on NEO

Stockrow Weekly